Lorvotuzumab

• Description:

  Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab) ) is a humanized monoclonal antibody that binds CD56 (NCAM1) . Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine[1].

• Product Name Alternative:

  Anti-NCAM1/ CD56 Reference Antibody (lorvotuzumab)

• UNSPSC:

  12352203

• Target:

  ADC Antibody

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lorvotuzumab.html

• Purity:

  99.77

• Solubility:

  10 mM in DMSO

• Smiles:

  [Lorvotuzumab]

• Molecular Weight:

  (146.44 kDa)

• References & Citations:

  [1]James I Geller, et al. ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study. Cancer. 2020 Dec 15;126 (24) :5303-5310.

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 2

• CAS Number:

  339306-30-8